Number of items: 4.
Earl, Helena,
Hiller, Louise,
Vallier, Anne-Laure,
Loi, Shrushma,
McAdam, Karen,
Hughes-Davies, Luke,
Rea, Daniel,
Howe, Donna L.,
Raynes, Kerry,
Higgins, Helen B. et al.
(2020)
Six versus 12 monthsβ adjuvant trastuzumab in patients with HER2-positive early breast cancer : the PERSEPHONE non-inferiority RCT.
Health Technology Assessment, 24
(40).
pp. 1-190.
doi:
10.3310/hta24400
ISSN 1366-5278.
Earl, Helena M.,
Hiller, Louise,
Vallier, Anne-Laure,
Loi, Shrushma,
McAdam, Karen,
Hughes-Davies, Luke,
Harnett, Adrian N,
Ah-See, Mei-Lin,
Simcock, Richard,
Rea, Daniel et al.
(2019)
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE) : 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.
The Lancet, 393
(10191).
pp. 2599-2612.
doi:
10.1016/S0140-6736(19)30650-6
ISSN 0140-6736.
Hiller, Louise, Dunn, Janet A., Loi, Shrushma, Vallier, Anne-Laure, Howe, Donna L., Cameron, David A., Miles, David, Wardley, Andrew M. and Earl, Helena M.
(2018)
Adjuvant trastuzumab duration trials in HER2 positive breast cancer : what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results.
BMC Cancer, 18
.
391.
doi:10.1186/s12885-018-4307-8
ISSN 1471-2407.
Hiller, Louise, Loi, S., Vallier, A. L., Howe, Donna L., Bell, P., Carey, J., Manazar, Uzma, Cameron, D., Miles, D. and Wardley, A.
(2017)
Measurement methods for eliciting opinions on treatment benefits, toxicities and acceptable trade-offs of the two, within the PERSEPHONE trial.
Trials, 18
(Supplement 1).
p. 200.
P368 [pp139].
ISSN 1745-6215
doi:10.1186/s13063-017-1902-y
This list was generated on Thu Apr 25 00:32:35 2024 BST.